Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01568866 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 929
- Enrollment target
NCT01568866 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 929 participants.
The verdict
NCT01568866, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 929 participants
- Enrollment target
Study Summary
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Interventions
- DRUG Dexamethasone
- DRUG Carfilzomib
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 929 participants |
| Start Date | 2012-06-20 |
| Est. Completion | 2018-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01568866
The ClinicalTrials.gov registry entry for NCT01568866 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 929 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT01568866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01568866 about?
NCT01568866 is a clinical study titled "Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients". The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
What is the current status of trial NCT01568866?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 929 participants. The study started on 2012-06-20. Estimated completion is 2018-02-05.
What interventions are being tested in trial NCT01568866?
The interventions under investigation include: Dexamethasone (DRUG), Carfilzomib (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT01568866?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.